The EBF1 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the EBF1 transcription factor. This product is generated using CRISPR/Cas9-mediated gene disruption within the HAP1 host cell line, yielding a heterogeneous pool of edited cells. As a polyclonal knockout model, it circumvents clonal selection artifacts and provides a robust, population-level assessment of EBF1 deficiency. The knockout efficiently abrogates EBF1 function, enabling researchers to dissect its role in B-cell transcriptional programs without the confounding influence of residual protein activity. This cellular tool is ideal for high-throughput screening, pathway analysis, and mechanistic investigations requiring a consistent genetic background.
The HAP1 cell line is a human near-haploid chronic myeloid leukemia-derived cell line with a predominantly haploid karyotype, except for a disomic chromosome 8 segment. This unique genomic architecture simplifies genetic manipulations, as a single CRISPR/Cas9 event can disrupt both alleles of a target gene, facilitating the generation of homozygous knockout models. Originating from a CML patient, HAP1 cells retain features of the hematopoietic lineage but lack B-cell characteristics, making them a clean chassis for studying B-lineage transcription factor function. Their robust proliferation and adaptability to high-throughput formats further enhance their utility in functional genomics and drug discovery.
EBF1 is a pivotal pioneer transcription factor that orchestrates B-cell lineage commitment, differentiation, and maintenance. Mechanistically, EBF1 is activated upstream by IL-7 receptor signaling and pre-B cell receptor cues, working in concert with E2A (TCF3) and Runx1 to initiate B-cell specification. Once expressed, EBF1 directly binds and opens chromatin at key B-lineage loci, transcriptionally activating downstream targets such as CD79A, CD79B, PAX5, VPREB1, BLNK, and components of the V(D)J recombination machinery, including RAG1 and RAG2. EBF1 also interacts with TCF3, PAX5, Foxo1, IRF4, and Runx1 to stabilize the B-cell gene network. Disruption of EBF1 therefore removes a master regulatory node, silencing the pro-B-cell program and modeling early developmental arrest.
In the HAP1 context, EBF1 knockout provides a powerful model to investigate B-cell transcriptional networks free from endogenous B-lineage influences. The near-haploid nature of HAP1 cells simplifies the interpretation of knockout phenotypes, as gene disruption leads to unambiguous loss of function. Although HAP1 cells are not B cells, ectopic expression or complementation studies can reconstitute partial B-lineage modules, allowing dissection of EBF1-dependent versus -independent events. This system is particularly valuable for structure?Cfunction analyses, domain mapping of EBF1??s transactivation and DNA-binding capabilities, and exploring synthetic lethality with other B-cell factors. Moreover, the polyclonal format reduces the risk of clonal bias in drug sensitivity or proliferation assays, offering a more representative population-level response.
Typical applications of EBF1 Knockout HAP1 Polyclonal Cells include B-cell transcriptional network analysis through RNA-seq and ChIP-qPCR, where loss of EBF1 leads to downregulation of targets like CD79A and PAX5. Western blotting and RT-qPCR confirm EBF1 depletion and downstream effects. Co-immunoprecipitation with TCF3 or PAX5 can probe disrupted protein complexes. The model is suitable for drug target validation in B-ALL and lymphoma contexts, using drug sensitivity assays to identify compounds that selectively kill EBF1-deficient cells. Additionally, it supports haploinsufficiency studies and synthetic lethal screens in a near-haploid background. For additional technical details, contact Ascent Research.
